GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shionogi & Co Ltd (OTCPK:SGIOF) » Definitions » Beneish M-Score

Shionogi (Shionogi) Beneish M-Score : -2.23 (As of May. 25, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Shionogi Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.23 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shionogi's Beneish M-Score or its related term are showing as below:

SGIOF' s Beneish M-Score Range Over the Past 10 Years
Min: -2.76   Med: -2.08   Max: -1.37
Current: -2.23

During the past 13 years, the highest Beneish M-Score of Shionogi was -1.37. The lowest was -2.76. And the median was -2.08.


Shionogi Beneish M-Score Historical Data

The historical data trend for Shionogi's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shionogi Beneish M-Score Chart

Shionogi Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.76 -2.46 -1.97 -2.53 -2.23

Shionogi Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.53 -2.17 -1.80 -2.32 -2.23

Competitive Comparison of Shionogi's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shionogi's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shionogi's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shionogi's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shionogi's Beneish M-Score falls into.



Shionogi Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shionogi for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0488+0.528 * 0.9845+0.404 * 1.1513+0.892 * 0.9519+0.115 * 0.9427
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0004+4.679 * 0.00669-0.327 * 0.8007
=-2.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $820 Mil.
Revenue was 655.866 + 738.136 + 819.98 + 773.291 = $2,987 Mil.
Gross Profit was 554.41 + 637.318 + 720.106 + 680.485 = $2,592 Mil.
Total Current Assets was $5,234 Mil.
Total Assets was $9,458 Mil.
Property, Plant and Equipment(Net PPE) was $828 Mil.
Depreciation, Depletion and Amortization(DDA) was $126 Mil.
Selling, General, & Admin. Expense(SGA) was $683 Mil.
Total Current Liabilities was $894 Mil.
Long-Term Debt & Capital Lease Obligation was $58 Mil.
Net Income was 232.334 + 254.401 + 324.874 + 301.093 = $1,113 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was 582.224 + 149.484 + 95.702 + 222.018 = $1,049 Mil.
Total Receivables was $821 Mil.
Revenue was 660.887 + 1390.27 + 550.926 + 536.264 = $3,138 Mil.
Gross Profit was 528.608 + 1262.79 + 450.28 + 439.625 = $2,681 Mil.
Total Current Assets was $5,867 Mil.
Total Assets was $9,814 Mil.
Property, Plant and Equipment(Net PPE) was $887 Mil.
Depreciation, Depletion and Amortization(DDA) was $126 Mil.
Selling, General, & Admin. Expense(SGA) was $717 Mil.
Total Current Liabilities was $1,186 Mil.
Long-Term Debt & Capital Lease Obligation was $48 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(819.858 / 2987.273) / (821.266 / 3138.347)
=0.27445 / 0.261687
=1.0488

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(2681.303 / 3138.347) / (2592.319 / 2987.273)
=0.854368 / 0.867788
=0.9845

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (5234.363 + 827.841) / 9457.557) / (1 - (5866.877 + 887.051) / 9814.139)
=0.35901 / 0.311817
=1.1513

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2987.273 / 3138.347
=0.9519

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(125.866 / (125.866 + 887.051)) / (125.689 / (125.689 + 827.841))
=0.124261 / 0.131814
=0.9427

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(683.096 / 2987.273) / (717.343 / 3138.347)
=0.228669 / 0.228574
=1.0004

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((58.424 + 893.794) / 9457.557) / ((47.859 + 1186.196) / 9814.139)
=0.100683 / 0.125743
=0.8007

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1112.702 - 0 - 1049.428) / 9457.557
=0.00669

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shionogi has a M-score of -2.34 suggests that the company is unlikely to be a manipulator.


Shionogi Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Shionogi's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shionogi (Shionogi) Business Description

Traded in Other Exchanges
Address
1-8, Doshomachi 3-chome, Chuo-ku, Osaka, JPN, 541-0045
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Shionogi (Shionogi) Headlines

From GuruFocus

Shionogi & Co Ltd R&D Meeting Transcript

By GuruFocus Research 02-14-2024

Shionogi & Co Ltd R&D Meeting Transcript

By GuruFocus Research 02-14-2024